Holen Sie sich die Stockscreener-App
3.54
5.60%
-0.21
Schlusskurs vom Vortag:
$3.75
Offen:
$3.8
24-Stunden-Volumen:
1.61M
Relative Volume:
0.40
Marktkapitalisierung:
$455.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.78M
KGV:
-3.3084
EPS:
-1.07
Netto-Cashflow:
$-75.59M
1W Leistung:
-9.46%
1M Leistung:
-22.37%
6M Leistung:
-45.29%
1J Leistung:
-16.51%
1-Tages-Spanne:
$3.54
$3.82
1-Wochen-Bereich:
$3.54
$4.04
52-Wochen-Spanne:
$2.81
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Firmenname
Humacyte Inc
Sektor
Branche
Telefon
919-313-9633
Adresse
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Vergleichen Sie HUMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
3.54 | 455.49M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2023-12-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-14 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Eingeleitet | Cowen | Outperform |
| 2021-09-24 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-22 | Eingeleitet | BTIG Research | Buy |
| 2021-09-16 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
Lost Money on Humacyte, Inc. (HUMA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven? - Yahoo Finance UK
Humacyte stock rallies 19% on FDA RMAT designation - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Humacyte, Inc. to Contact the Firm Today! - ACCESS Newswire
Humacyte moves to test bioengineered vessel in heart surgery - MSN
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights - MSN
LJI Wealth Management LLC Purchases Shares of 185,000 Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
North Carolina biotech weighs demand as breakthrough treatment hits market - The Business Journals
Trilogy Capital Inc. Buys New Holdings in Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: What You Should Know - MSN
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why - MSN
Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Bullish Humacyte Insiders Loaded Up On US$803.3k Of Stock - Simply Wall St
Investing in Humacyte Inc (HUMA) Is Getting More Attractive - Knox Daily
Financial Analysis: Humacyte Inc (HUMA)’s Ratios Unveil Key Insights - The Dwinnex
Examining Humacyte Inc (HUMA) more closely is necessary - US Post News
Wealth Effects LLC Buys 57,200 Shares of Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMAW) Trading Down 1% – What’s Next? - Defense World
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL
Humacyte and Pluristyx enhance partnership for diabetes treatment By Investing.com - Investing.com South Africa
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Humacyte, Pluristyx Announce Gene Editing Partnership -January 28, 2025 at 12:05 pm EST - Marketscreener.com
Humacyte and Pluristyx enhance partnership for diabetes treatment - Investing.com India
Humacyte and Pluristyx Announces Gene Editing Partnership to Support BioVascular Pancreas (BVP?) Development Using iPSCs - Marketscreener.com
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs - The Manila Times
Revolutionary Diabetes Breakthrough: Gene-Edited Cell Technology Could End Daily Insulin Injections - StockTitan
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - accessnewswire.com
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2 Firms Want To Co-Lead Humacyte Investor Suit - Law360
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Investors to Inquire about Securities Investigation - ACCESS Newswire
Humacyte: Upside Potential, But I Will Wait For Revenue Trends - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Humacyte, Inc. (HUMA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Humacyte, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationHUMA - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - ACCESS Newswire
Cantor Fitzgerald Comments on Humacyte FY2025 Earnings - Defense World
Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital - Defense World
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Cantor Fitzgerald Estimates Humacyte FY2025 Earnings - MarketBeat
Humacyte moves to test bioengineered vessel in heart surgery By Investing.com - Investing.com Australia
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law - GlobeNewswire
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - GlobeNewswire Inc.
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
Finanzdaten der Humacyte Inc-Aktie (HUMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):